Top Pharmaceutical Contract Development and Manufacturing Companies

Global Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 150.12 Billion in 2024 and is poised to grow from USD 160.06 Billion in 2025 to USD 267.29 Billion by 2033, growing at a CAGR of 6.62% during the forecast period (2026–2033).

To improve their market position, players in the industry are concentrating on agreements, partnerships, collaborations, acquisitions, and other tactics. Pharma firms must provide more and better new pharmaceuticals to combat the diseases to which the human body is susceptible in order to combat the rising number of new diseases. 'Cambrex Corporation ', 'Samsung Biologics Co., Ltd. ', 'Siegfried Holdings AG ', 'FUJIFILM Diosynth Biotechnologies ', 'Aenova Group ', 'Wuxi Biologics, Inc. ', 'Aurobindo Pharma, Ltd. ', 'Vetter Pharma International GmbH ', 'Thermo Fisher Scientific, Inc. ', 'Catalent, Inc ', 'Recipharm AB ', 'Almac Group ', 'Lonza Group Ltd. ', 'Piramal Enterprises Limited ', 'Fabbrica Italiana Sintetici S.p.A. ', 'Fareva SA ', 'C.H. Boehringer Sohn AG & Co. KG. ', 'Jubilant Pharmova Limited ', 'Curia Global, Inc. ', 'Delpharm Holdings '

The market is being driven by the advantages of outsourcing, namely the savings in time and money. To increase their share of outsourcing revenue, market players frequently spend on infrastructure, staff, and technology.

With the rise in cancer incidence and the creation of safe and efficient medications thanks to technical advancements, the market for oncology treatments has expanded quickly. Because of the growing demand for potent, focused medicines and the ability of compounds to be more selective towards the target of interest to reduce dosing frequencies, there is an increasing interest in highly potent New Chemical Entities (NCEs).

The pharmaceutical contract development and manufacturing market is anticipated to be dominated by North America in 2022, followed by Europe and Asia-Pacific. The substantial share of this region is primarily linked to expanding generic medicine and biologics demand, CDMO consolidation, rising need for biosimilars due to patent expiry, and rising outsourcing costs. Furthermore, the focus on pharmaceutical and biotechnology research by organisations has made the contract manufacturing business in North America extremely competitive.